Bacterial vaginosis
diseaseOn this page
Also known as BV
Summary
Bacterial vaginosis (MONDO:0005316) is a disease and 157 clinical trials. Top therapeutic interventions include metronidazole, clindamycin, and dequalinium. A subtype of Bifidobacteriales infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 157
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | bacterial vaginosis |
| Mondo ID | MONDO:0005316 |
| EFO | EFO:0003932 |
| MeSH | D016585 |
| DOID | DOID:3385 |
| ICD-11 | 63323819 |
| NCIT | C116973 |
| SNOMED CT | 419760006 |
| UMLS | C0085166 |
| MedGen | 43118 |
| Is cancer (heuristic) | no |
Also known as: BV
Disease family
This is a subtype of Bifidobacteriales infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › Bifidobacteriales infectious disease › bacterial vaginosis
Related subtypes (1): infection caused by Bifidobacterium
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
4 approved, 9 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Clindamycin Phosphate | Approved (phase 4) |
| Metronidazole | Approved (phase 4) |
| Secnidazole | Approved (phase 4) |
| Tinidazole | Approved (phase 4) |
| Amphotericin B | Phase 3 (in late-stage trials) |
| Astodrimer | Phase 3 (in late-stage trials) |
| Clindamycin | Phase 3 (in late-stage trials) |
| Clotrimazole | Phase 3 (in late-stage trials) |
| Dexamethasone | Phase 3 (in late-stage trials) |
| Fluconazole | Phase 3 (in late-stage trials) |
| Ketoconazole | Phase 3 (in late-stage trials) |
| Nystatin | Phase 3 (in late-stage trials) |
| Tetracycline | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Amoxicillin, Boric Acid, Dextrose, Rifaximin, Sodium Chloride.
Clinical trials & evidence
Clinical trials
Clinical trials: 157.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 61 |
| PHASE3 | 27 |
| PHASE4 | 21 |
| PHASE2 | 17 |
| PHASE1 | 12 |
| EARLY_PHASE1 | 8 |
| PHASE2/PHASE3 | 7 |
| PHASE1/PHASE2 | 4 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04771728 | PHASE4 | RECRUITING | A Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis |
| NCT06349122 | PHASE4 | NOT_YET_RECRUITING | Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth |
| NCT06458543 | PHASE4 | RECRUITING | Optimization of Bacterial Vaginosis Treatment in Women of Reproductive Age |
| NCT00324818 | PHASE4 | COMPLETED | Treatment of Bacterial Vaginosis |
| NCT00334633 | PHASE4 | COMPLETED | Treatment of Bacterial Vaginosis (BV) With Tinidazole |
| NCT00464542 | PHASE4 | COMPLETED | Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study |
| NCT00556179 | PHASE4 | COMPLETED | Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis |
| NCT01245322 | PHASE4 | COMPLETED | Treatment of Bacterial Vaginosis Combined With Human Lactobacilli |
| NCT01558388 | PHASE4 | UNKNOWN | Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy |
| NCT01800825 | PHASE4 | COMPLETED | Clindamycin to Reduce Preterm Birth in a Low Resource Setting |
| NCT01841411 | PHASE4 | UNKNOWN | Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis |
| NCT02042287 | PHASE4 | COMPLETED | Treatment Comparison of Antibiotics Versus Vaginal Lactic Acid in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis |
| NCT02432404 | PHASE4 | COMPLETED | Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity |
| NCT02445989 | PHASE4 | COMPLETED | Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity |
| NCT02905890 | PHASE4 | COMPLETED | The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis |
| NCT03080740 | PHASE4 | UNKNOWN | The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis |
| NCT03099408 | PHASE4 | COMPLETED | Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis |
| NCT03839875 | PHASE4 | COMPLETED | Evaluation of Efficacy and Safety of Gynomax® XL Ovule |
| NCT03894813 | PHASE4 | COMPLETED | Probiotics as Adjuvant Treatment for Bacterial Vaginosis |
| NCT05060029 | PHASE4 | UNKNOWN | A Pilot Study to Evaluate the Efficacy and Safety of Lactobacillus Species Suppositories on Vaginal Health and pH |
| NCT05788991 | PHASE4 | TERMINATED | Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis |
| NCT07527572 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis |
| NCT00124878 | PHASE3 | UNKNOWN | Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community |
| NCT00140764 | PHASE3 | COMPLETED | Intravaginal Treatment of Disturbances of Vaginal Flora Among HIV Infected and Uninfected Women in Malawi |
| NCT00229216 | PHASE3 | COMPLETED | Treatment of Bacterial Vaginosis With Oral Tinidazole |
| NCT00303082 | PHASE3 | TERMINATED | Probiotics for the Prevention of Premature Birth and Neonatal Related Morbidity |
| NCT00313131 | PHASE3 | COMPLETED | Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments |
| NCT00536848 | PHASE2/PHASE3 | UNKNOWN | The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients |
| NCT00667368 | PHASE3 | COMPLETED | Bacterial Vaginosis Home Screening to Prevent STDs |
| NCT00741845 | PHASE3 | TERMINATED | Prevention of Persistence of Bacterial Vaginosis |
| NCT00799214 | PHASE2/PHASE3 | COMPLETED | BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study |
| NCT00889356 | PHASE3 | UNKNOWN | Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis |
| NCT01089348 | PHASE2/PHASE3 | UNKNOWN | A Pilot Open-label Randomized Study of Lactofiltrum in Women With Bacterial Vaginosis |
| NCT01125410 | PHASE3 | COMPLETED | Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis |
| NCT01152528 | PHASE3 | UNKNOWN | Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery |
| NCT01160796 | PHASE3 | COMPLETED | Lcr35® for Bacterial Vaginosis Prevention |
| NCT01258556 | PHASE2/PHASE3 | COMPLETED | The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis |
| NCT01471457 | PHASE2/PHASE3 | COMPLETED | Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis |
| NCT01577238 | PHASE3 | COMPLETED | A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis |
| NCT01577537 | PHASE3 | COMPLETED | A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| METRONIDAZOLE | 4 | 35 |
| CLINDAMYCIN | 4 | 9 |
| DEQUALINIUM | 4 | 6 |
| TINIDAZOLE | 4 | 5 |
| SECNIDAZOLE | 4 | 4 |
| CEFTRIAXONE | 4 | 2 |
| CHLORHEXIDINE | 4 | 2 |
| CLINDAMYCIN PHOSPHATE | 4 | 2 |
| CLOTRIMAZOLE | 4 | 2 |
| ACETYLCYSTEINE | 4 | 1 |
| AZITHROMYCIN | 4 | 1 |
| CLINDAMYCIN PALMITATE | 4 | 1 |
| NORETHINDRONE | 4 | 1 |
| NYSTATIN | 4 | 1 |
| PENICILLIN G | 4 | 1 |
| BORIC ACID | 3 | 1 |
| LACTOBACILLUS ACIDOPHILUS | 3 | 1 |
| POLYETHYLENE GLYCOL | 3 | 1 |
| CHEMBL4299381 | 0 | 1 |
| CHEMBL450895 | 0 | 1 |
| CHEMBL4791312 | 0 | 1 |
| 17 | 0 | 1 |